Amgen (AMGN) said Friday that a phase 3 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung cancer met its primary endpoint at a planned interim analysis.

The biopharmaceutical company said the data show that Imdelltra demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.

Amgen said the randomized open-label clinical trial is evaluating the efficacy and safety of Imdelltra as a treatment for patients with SCLC who progressed on or after a single line of platinum-based chemotherapy.